Aveo-Astellas kidney cancer drug is not recommended by FDA advisers

05/3/2013 | Yahoo

An FDA advisory panel voted 13-1 against recommending approval of Aveo Pharmaceuticals and Astellas Pharma's tivozanib as treatment for kidney cancer, citing inconsistent data from a clinical trial. The panel said another trial would be needed. Though disappointed with the decision, Aveo and Astellas said they would consult with the agency to address the advisers' concerns.

View Full Article in:

Yahoo

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ